CD38 and plasma cell myeloma: As a consequence, there is increasing interest in combinatorial immunologically based strategies that employ BCMA with other validated myeloma targets, such as CD38, SLAMF7, and CD19 [263] or with emerging viable targets like GPRC5D [215,264].